RNTX

#4160
Rein Therapeutics, Inc. - Common Stock
0.7 5 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.75
0.75
Jahresspanne
0.69
2.10
Tagesänderung
-1.32%
Monatliche Änderung
+2.74%
6 month change
-35.34%
Jahresänderung
-31.84%
Vorheriger Schlusskurs
0.7 6
Open
0.7 5
Tief
0.7 5
Hoch
0.7 5
Volumen
8
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, 21 Aug 2026
Rein Therapeutics, Inc. current report, 21 August 2026
8-K
Current report, Q3 FY2026
Rein Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Rein Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Rein Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Rein Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Rein Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Rein Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Rein Therapeutics, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Rein Therapeutics, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Rein Therapeutics, Inc. current report, Q4 FY2025
8-K

Rein Therapeutics, Inc. current report, Q3 FY2026

Full document

Rein Therapeutics, Inc. (RNTX) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held on July 20, 2026. The filing details the outcomes of four key proposals submitted to shareholders for a vote.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.

Material Changes and Voting Results

Shareholders approved the following matters:

  • Director Elections: Two Class III directors were elected to serve until the 2029 annual meeting:
    • Josef H. von Rickenbach: 25,402,442 votes For; 13,202,963 votes Withheld.
    • Reinhard J. Ambros, Ph.D.: 25,404,238 votes For; 13,201,167 votes Withheld.
  • Authorized Share Increase: An amendment to the restated certificate of incorporation was approved to increase authorized common stock from 100 million to 200 million shares.
    • Votes For: 61,004,221
    • Votes Against: 2,394,208
    • Abstain: 305,605
  • Independent Auditor Ratification: CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
    • Votes For: 62,953,351
    • Votes Against: 172,420
    • Abstain: 578,263
  • Executive Compensation: Shareholders approved, on an advisory basis, the compensation of named executive officers.
    • Votes For: 37,628,483
    • Votes Against: 914,331
    • Abstain: 62,591
    • Broker Non-Votes: 25,098,629

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of the voting results.

Key Facts for Investor Verification

  • Verify the impact of doubling the authorized share count from 100 million to 200 million on potential future dilution.
  • Note the significant number of broker non-votes (approx. 25.1 million) on the executive compensation advisory vote, indicating a large portion of shares were held by brokers without discretionary voting power on this specific item.
  • Confirm the tenure of the newly elected directors, Josef H. von Rickenbach and Reinhard J. Ambros, extending through the 2029 annual meeting.
  • Review the full Proxy Statement referenced in the filing for detailed executive compensation data.